Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial

Journal:
European Urology
Published:
DOI:
10.1016/j.eururo.2025.10.001
Affiliations:
12
Authors:
16
Go to article
Institutions Authors Share
Karolinska Institute (KI), Sweden
11.500000
11.500000
 0.72
The University of Chicago (UChicago), United States of America (USA)
1.000000
 0.06
University of California, San Francisco (UCSF), United States of America (USA)
1.000000
 0.06
UW Medical Center (UWMC), United States of America (USA)
0.500000
 0.03
Fred Hutchinson Cancer Center, United States of America (USA)
0.500000
 0.03
Danderyd Hospital (DS), Sweden
0.500000
 0.03
Martini-Klinik, UHH, Germany
0.500000
 0.03
Koç University Hospital, Turkey
0.500000
 0.03
Interested in Oncology and Carcinogenesis?